Subscribe
Home
Daily Tape
Research Hub
Blog
About
Subscribe
Join 2,000+ investors
The biotech deal tape in your inbox. Free.
✓
Top news, M&A, BD&L, IPOs and VC — every morning
✓
Deal economics with investor-grade context
✓
Research Hub access: live trackers updated weekly
✓
5 minutes. Published every weekday.
Get the tape →
Latest Editions
Daily
Sep 4
Friday: Ionis lands a first, GSK pays $110M for a pre-IND molecule
An ultra-rare approval, a 74% response rate, and a licence signed before Phase 1.
Sep 3
Thursday: Ultragenyx drops 44% after the bell
A clean Phase 3 miss, an FDA warning shot, and $3.22B for a better needle.
Sep 2
Wednesday: Novartis wins in MS, Alumis drops 54%
Two Phase 3 wins for a BTK pill, and Roche writes another China check.
Sep 1
Tuesday: 3 deaths freeze CAR-T, 9 more names sign MFN
Class-wide safety scare, a 26-name pricing club, and ARCH goes shopping for $3B.
Aug 31
Monday: Lilly drops $2.9B on Merida as Wainua stumbles in Munich
ESC hands out a split verdict; Takeda's $275M cheque clears on the way.
